Physician profile
Roberto Daniel Chang
NPI 1669608923
$13,280.92
in general payments reported to CMS, 2019-2025
49 companies · $4,075 in 2025
The $4,075 reported for 2025 was more than what 89% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,324 · 2020: $733 · 2021: $2,455 · 2022: $1,244 · 2023: $1,630 · 2024: $1,820 · 2025: $4,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,255 · Travel and Lodging: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,255.05 |
| Travel and Lodging | $1,270.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,923.81 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Clinical Trial Product |
| Mml US, INC. | $1,699.26 | 2025 | Reactiv8 |
| Biotronik Nro, INC. | $870.74 | 2025 | Prospera |
| Collegium Pharmaceutical, INC. | $703.36 | 2019-2025 | Belbuca, Xtampza |
| Pfizer INC. | $617.81 | 2019-2025 | |
| Forte Bio-Pharma LLC | $511.15 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Abbvie INC. | $336.02 | 2021-2024 | Ubrelvy |
| Spr Therapeutics, INC | $321.61 | 2024-2025 | Sprint Pns System |
| Abbott Laboratories | $291.74 | 2019-2025 | Proclaim |
| Scilex Pharmaceuticals INC. | $273.42 | 2019-2024 | Ztlido |
| Amgen INC. | $225.03 | 2019-2022 | |
| Spinal Simplicity, LLC | $198.26 | 2024-2025 | Ha Minuteman G3-R |
| Redhill Biopharma INC. | $180.11 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $177.67 | 2021-2023 | Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.07 | 2019-2025 | Relistor |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.